Quralis

Risk score

57
Large logo of Quralis

Headquarters

Flag of United States of AmericaUnited States of America

QurAlis is focused on developing precise therapeutics for ALS, an incurable condition that leads to muscle paralysis due to the decline of the motor system. The company is delving deep into the fundamental causes of the various subtypes of this devastating illness and directing its efforts towards addressing specific disease-causing mechanisms. QurAlis' approach involves targeting individual genes associated with ALS using an innovative system that utilizes cells from ALS patients to replicate the disease in a laboratory setting, enabling the identification of new drugs. Kevin Eggan and Clifford Woolf, both professors at Harvard, are the co-founders of QurAlis and have been instrumental in developing this groundbreaking technology for treating ALS.